<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648852</url>
  </required_header>
  <id_info>
    <org_study_id>LH-20H4HF</org_study_id>
    <nct_id>NCT04648852</nct_id>
  </id_info>
  <brief_title>The HUNT for Heart Failure&quot; Risk Score</brief_title>
  <acronym>HUNT4HF</acronym>
  <official_title>Heart Failure Burden and Heart Failure Risk in the General Population in Norway: &quot;The HUNT for Heart Failure&quot; Risk Score</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Nord-Trøndelag HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Nord-Trøndelag HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this population study aim is to evaluate risk factors for heart failure and combine these&#xD;
      into a new heart failure risk score.&#xD;
&#xD;
      Secondly, the heart failure risk score will be internally and externally validated, and&#xD;
      compared with established heart failure risk scores. Additionally, the prevalence of heart&#xD;
      failure as well as the distribution of the heart failure risk score in the general population&#xD;
      will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explore which clinical risk factors or patient characteristics in a general population that&#xD;
      are associated with increased risk for heart failure events and combine these into a new&#xD;
      population-based heart failure risk score (&quot;The HUNT for heart failure risk score&quot;) for&#xD;
      predicting heart failure risk&#xD;
&#xD;
      Validate the newly developed heart failure risk score internally in the HUNT2 database&#xD;
&#xD;
      Compare the predictive ability of the new heart failure risk score with established heart&#xD;
      failure risk scores (the ABC Health HF risk score, the Framingham HF risk score) and an&#xD;
      established Norwegian cardiovascular risk score (NORRISK 2)&#xD;
&#xD;
      Estimate the prevalence of likely (&quot;undiagnosed&quot;) heart failure , i.e., patients at high risk&#xD;
      of HF, in a general population by using both the established heart failure risk scores and&#xD;
      the newly developed heart failure risk score, and compare the heart failure event rate&#xD;
      between those at high risk of heart failure and those with established heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Time to incident heart failure event</measure>
    <time_frame>10 years</time_frame>
    <description>Time to first heart failure hospitalization or heart failure related visit at the out-patient clinic (events defined according to the ESC 2016 heart failure guidelines)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death from any cause</measure>
    <time_frame>10 years</time_frame>
    <description>Time to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first heart failure event or death from any cause</measure>
    <time_frame>10 years</time_frame>
    <description>Time to first heart failure event (hospitalization or HF related visit at the out-patient clinic) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validity of heart failure risk score</measure>
    <time_frame>10 years</time_frame>
    <description>Evaluation of the validity of heart failure risk score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prevalence of heart failure</measure>
    <time_frame>0 days</time_frame>
    <description>Prevalence of heart failure in a general population</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of heart failure risk score categories</measure>
    <time_frame>0 days</time_frame>
    <description>Distribution of the heart failure risk score categories in a general population</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">65000</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Participants in the third wave of the HUNT study</arm_group_label>
    <description>General population participating in the third wave of the HUNT study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants in the second wave of the HUNT study</arm_group_label>
    <description>General population participating in the second wave of the HUNT study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart failure risk estimation</intervention_name>
    <description>Evaluation by heart failure risk score</description>
    <arm_group_label>Participants in the second wave of the HUNT study</arm_group_label>
    <arm_group_label>Participants in the third wave of the HUNT study</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biobank available, but not included in this project. Laboratory test made available are&#xD;
      haematology overview, renal function serology, C-reactive protein&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        General population&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in the third or second wave of the HUNT study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not willing to participate&#xD;
&#xD;
          -  Missing vital data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håvard Dalen, MSc, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Helse Nord-Trøndelag HF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Levanger hospital</name>
      <address>
        <city>Levanger</city>
        <state>Norge</state>
        <zip>7600</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>risk factor</keyword>
  <keyword>population</keyword>
  <keyword>diagnosis</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Will follow the institutional regulations</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

